ResearcherAzienda Ospedaliero-Universitaria di ModenaNo recent work listed
Giulia Rovesti
Matched on ORCID iD 0000-0002-2761-9482; OpenAlex author ID A5020405049. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2019: 2 papers · 2020: 1 paper · 2021: 3 papers
Papers 6
- Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Co-author DOI 10.1177/0300891620976945↗
- Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. Co-author DOI 10.3390/nu13103522↗
- TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. First author PMID 34659901↗
- First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Co-author DOI 10.1016/j.ejca.2020.06.031↗
- Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-37433-6↗
- MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Co-author DOI 10.7150/thno.27576↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Massimo Dominici · 4 shared papers, 2019–2021 · strength 0.39
- Paper Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of … DOI 10.3390/nu13103522↗
- Paper TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. PMID 34659901↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Carlotta Spano · 3 shared papers, 2019–2021 · strength 0.25
- Paper TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. PMID 34659901↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Paper Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. DOI 10.1038/s41598-018-37433-6↗
- Giulia Grisendi · 3 shared papers, 2019–2021 · strength 0.25
- Paper TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. PMID 34659901↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Paper Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. DOI 10.1038/s41598-018-37433-6↗
- Andrea Spallanzani · 2 shared papers, 2021 · strength 0.24
- Giulia Orsi · 3 shared papers, 2019–2021 · strength 0.24
- Paper Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type … DOI 10.1177/0300891620976945↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Paper Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. DOI 10.1038/s41598-018-37433-6↗
- Kalliopi Andrikou · 2 shared papers, 2020–2021 · strength 0.19
- Paper Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type … DOI 10.1177/0300891620976945↗
- Paper First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontie… DOI 10.1016/j.ejca.2020.06.031↗
- Stefano Cascinu · 2 shared papers, 2019–2021 · strength 0.17
- Filippo Rossignoli · 2 shared papers, 2019 · strength 0.14
- Giulia Golinelli · 2 shared papers, 2019 · strength 0.14
- Renata Menozzi · 1 shared paper, 2021 · strength 0.13
- Massimiliano Dall’Ora · 1 shared paper, 2021 · strength 0.11
- Mario Scartozzi · 1 shared paper, 2021 · strength 0.09
- Andrea Pretta · 1 shared paper, 2021 · strength 0.09
- Eleonora Lai · 1 shared paper, 2021 · strength 0.09
- Luca Faloppi · 1 shared paper, 2021 · strength 0.09
- Caterina Vivaldi · 1 shared paper, 2020 · strength 0.09
- Silvia Catanese · 1 shared paper, 2020 · strength 0.09
- Vincenzo Formica · 1 shared paper, 2020 · strength 0.09
- Irene Pecora · 1 shared paper, 2020 · strength 0.09
- Lorenzo Fornaro · 1 shared paper, 2020 · strength 0.09
- Enrico Vasile · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.